David A. Siegel Tyra Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 50,100 shares of TYRA stock, worth $531,561. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,100
Previous 12,300
307.32%
Holding current value
$531,561
Previous $170,000
173.53%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TYRA
# of Institutions
119Shares Held
55.6MCall Options Held
25KPut Options Held
5.4K-
Ra Capital Management, L.P. Boston, MA10.6MShares$113 Million2.05% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.14MShares$44 Million95.26% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY4.08MShares$43.3 Million90.83% of portfolio
-
Nextech Invest Ag4.06MShares$43 Million10.51% of portfolio
-
Nextech Invest, Ltd. Zurich, V84.06MShares$43 Million8.77% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $445M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...